###begin article-title 0
###xml 168 174 <span type="species:ncbi:9606">Person</span>
Homozygosity for a missense mutation in the 67 kDa isoform of glutamate decarboxylase in a family with autosomal recessive spastic cerebral palsy: parallels with Stiff-Person Syndrome and other movement disorders
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Cerebral palsy (CP) is an heterogeneous group of neurological disorders of movement and/or posture, with an estimated incidence of 1 in 1000 live births. Non-progressive forms of symmetrical, spastic CP have been identified, which show a Mendelian autosomal recessive pattern of inheritance. We recently described the mapping of a recessive spastic CP locus to a 5 cM chromosomal region located at 2q24-31.1, in rare consanguineous families.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 169 173 169 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAD1</italic>
###xml 227 229 227 229 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67</sub>
Here we present data that refine this locus to a 0.5 cM region, flanked by the microsatellite markers D2S2345 and D2S326. The minimal region contains the candidate gene GAD1, which encodes a glutamate decarboxylase isoform (GAD67), involved in conversion of the amino acid and excitatory neurotransmitter glutamate to the inhibitory neurotransmitter gamma-aminobutyric acid (GABA).
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 44 47 44 47 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67 </sub>
A novel amino acid mis-sense mutation in GAD67 was detected, which segregated with CP in affected individuals.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 57 60 57 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67 </sub>
###xml 91 94 91 94 <sub xmlns:xlink="http://www.w3.org/1999/xlink">65 </sub>
###xml 119 124 119 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAD2 </italic>
###xml 315 320 315 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAD1 </italic>
###xml 147 155 <span type="species:ncbi:9606">patients</span>
###xml 167 173 <span type="species:ncbi:9606">Person</span>
This result is interesting because auto-antibodies to GAD67 and the more widely studied GAD65 homologue encoded by the GAD2 gene, are described in patients with Stiff-Person Syndrome (SPS), epilepsy, cerebellar ataxia and Batten disease. Further investigation seems merited of the possibility that variation in the GAD1 sequence, potentially affecting glutamate/GABA ratios, may underlie this form of spastic CP, given the presence of anti-GAD antibodies in SPS and the recognised excitotoxicity of glutamate in various contexts.
###end p 9
###begin p 10
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAD1</italic>
###xml 249 306 249 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nucleotide positions were not provided by Maestrini et al</italic>
GAD1 single nucleotide substitutions detected on mutation analysis and occurring in sequences submitted to NCBI SNP database and in the literature. This is not a definitive list, but includes those described at the time of the mutational analysis. *Nucleotide positions were not provided by Maestrini et al. [47].
###end p 10
###begin title 11
Background
###end title 11
###begin p 12
###xml 67 68 67 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 199 200 199 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 317 318 317 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 616 617 616 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 810 811 810 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 953 954 953 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 955 956 955 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 393 400 <span type="species:ncbi:9606">infants</span>
###xml 639 646 <span type="species:ncbi:9606">infants</span>
Cerebral palsy (CP) is a term used to define a group of disorders [1] characterized by a non-progressive abnormality of posture and movement, resulting from defects in the developing nervous system [2]. Approximately 1 in 250 to 1000 live births presents with CP, making it one the commonest congenital disabilities [3]. Many different aetiological factors have been implicated. Among preterm infants, the incidence of CP generally increases with decreasing gestational age and the origin in most cases may be traced to post/peri-partum periventricular leukomalacia and intraventricular/periventricular haemorrhage [4]. Conversely in term infants perinatal causes can only confidently be attributed where there is documented perinatal hypoxia/acidosis and clinical encephalopathy in the early neonatal period [5]. Prenatal risk factors in the aetiology of CP include low birth-weight, intrauterine infection and exposure to teratogens during pregnancy [6,7]. The cause in a large proportion of cases remains obscure.
###end p 12
###begin p 13
###xml 104 105 104 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 106 107 106 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 467 469 467 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 726 728 726 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
Depending on the overall clinical picture, CP can be sub-classified into a number of phenotypic groups [8,9]. Dyskinetic CP accounts for ~20% of all cases, which may be further divided into choreoathetotic (5%) and dystonic (15%) forms. Ataxic CP (~10% of all cases) can also be sub-divided into two forms, simple (congenital) ataxia (5%) and ataxic diplegia (5%). Spastic CP is the most prevalent sub-type (~70%) and was the phenotype of the probands in this study [10]. It is characterised by muscular hypertonicity and pronounced rigidity of the affected limbs. Spastic CP can be sub-classified according to the topography of the affected limbs as hemiplegic (20%), monoplegic (<1%), diplegic (40%), or quadriplegic (10%) [11].
###end p 13
###begin p 14
###xml 19 20 19 20 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 424 426 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 427 429 427 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 536 537 536 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 538 540 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 541 542 541 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 713 715 713 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 280 287 <span type="species:ncbi:9606">infants</span>
###xml 292 300 <span type="species:ncbi:9606">children</span>
Kuban and Leviton [3] suggested that CP could be genetic in origin, as well as the result of environmental insult at any point during CNS development. Most estimates place the proportion of CP cases with a genetic aetiology at between one and two percent of the total [12]. Among infants and children with spasticity, symmetry of neurological signs has been identified as a strong indicator of a probable genetic aetiology [13,14]. The proportion of cases demonstrating Mendelian inheritance varies among the different sub-types of CP [2,13,7]. X-linked, autosomal dominant and recessive inheritance patterns have been described for non-progressive CP. An ataxic diplegic autosomal recessive trait (OMIM:605388) [15] has been mapped to chromosome 9p12-q12. Progressive spastic paraplegia (SPG) has a similar pathology to CP. SPG displays autosomal dominant (SPG3A at 14q11-q21 encoding the atlastin GTPase; SPG4 at 2p21-22 encoding spastin, an AAA family ATPase/chaperonin; SPG6 at 15q11.1; SPG8 at 8q23-q24; SPG9 at 10q23-q24; SPG10 at 12q13; SPG12 at 19q13; and SPG13 at 2q24 encoding the HSP60 mitochondrial chaperonin), recessive (SPG5A at 8cen; SPG7 at 16q24.3 encoding paraplegin, an AAA family ATPase/inner mitochondrial membrane chaperonin; SPG11 at 15q13-q15; SPG14 at 3q27-q28; SPG15 at 14q22-q24; and SPG17 at 11q12-q14), or X-linked inheritance patterns (SPG1 at Xq28 encoding the L1CAM adhesion molecule; SPG2 at Xq22 encoding proteolipid protein-1; and SPG16 at Xq11.2).
###end p 14
###begin p 15
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1017 1021 1017 1021 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAD1</italic>
###xml 928 933 <span type="species:ncbi:9606">human</span>
A non-progressive, autosomal recessive, symmetrical spastic CP locus has been mapped to a 5 cM region between D2S124 and D2S333, at 2q24-31.1 (LOD score of 5.75) in consanguineous families originating from the Mirpur region of Pakistan (OMIM:603513) [10]. Affected individuals had no identifiable perinatal cause of CP, or underlying diagnosis and presented with developmental delay, mental retardation and sometimes epilepsy as part of the phenotype. We initially performed detailed physical mapping of the 5 cM region, so as to accurately define the marker order and to refine the linkage interval. The positions of a large number of genes and ESTs were defined accordingly, allowing the rapid identification of candidate disease genes. The minimum region of homozygosity was reduced to 0.5 cM by typing large numbers of microsatellite markers in the families. Subsequently, portions of this region have been sequenced in the human genome project. Within the region we have concentrated on the positional candidate GAD1, which codes for the 67 kDa isoform of L-glutamate decarboxylase (GAD EC:4.1.1.15).
###end p 15
###begin p 16
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 184 189 184 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAD1 </italic>
###xml 193 198 193 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAD2 </italic>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 435 437 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 446 448 446 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N-</italic>
###xml 493 495 493 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C-</italic>
###xml 599 601 599 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 830 832 830 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 978 980 978 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1147 1152 1147 1152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAD1 </italic>
GAD requires the cofactor pyridoxal 5'-phosphate (PLP) and catalyses the production of Gamma-aminobutyric acid (GABA) from glutamate [16]. Two separate, independently-regulated genes, GAD1 and GAD2 (at chromosome 10p11, encoding a 65 kDa GAD isoform), have presumably arisen by duplication and been conserved during evolution, as indicated by their sequence homology [17] and the retention of common intron-exon boundary splice sites [18]. Their N-termini demonstrate ~23% homology, but their C-termini, which contain the catalytic site, have ~73% amino acid sequence identity between the isoforms [19]. GABA and glutamate are the most abundant amino acid neurotransmitters in the brain. GABA, an inhibitory neurotransmitter, and excitatory glutamate, both play important roles in synaptic plasticity and neuroendocrine function [20]. Both isoforms of GAD are also involved in intermediary metabolism, participating in the GABA shunt, which bypasses two steps of the TCA cycle [21]. GAD activity of both isoforms, is ubiquitous, but highest in the brain and pancreatic islets of Langerhans. We therefore performed detailed mutational screening of GAD1 in familial spastic CP probands and unaffected family members.
###end p 16
###begin title 17
Methods
###end title 17
###begin title 18
Features and pedigrees of ascertained families
###end title 18
###begin title 19
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Family A </italic>
Family A (4718/4719)
###end title 19
###begin p 20
The oldest affected male diagnosed with non-progressive, spastic CP, demonstrated global developmental delay, with no associated neurological abnormalities and moderate mental retardation. His affected younger sister was also diagnosed with spastic CP, global developmental delay and moderate mental retardation.
###end p 20
###begin title 21
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Family B </italic>
Family B (4578/4579/4581/4679)
###end title 21
###begin p 22
###xml 594 596 594 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 597 599 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 304 311 <span type="species:ncbi:9606">patient</span>
The oldest non-progressive, spastic CP female has severe mental retardation, and is confined to a wheelchair. The next oldest spastic CP male has severe mental retardation, mild hypertonia and ataxia of the upper limbs. The next oldest spastic CP male is a dizygotic twin born by Caesarean section. This patient on presentation demonstrated developmental delay, mild hypertonia and ataxia of the upper limbs. The youngest affected female is not able to walk or stand unaided and has severe developmental delay. Details of the clinical picture in these pedigrees have been described previously [10,14].
###end p 22
###begin title 23
Physical mapping of candidate region
###end title 23
###begin p 24
###xml 141 146 <span type="species:ncbi:9606">human</span>
###xml 219 224 <span type="species:ncbi:9606">human</span>
ICI and CEPH YAC libraries were screened by PCR amplification of STSs that were mapped between D2S2157 and D2S385. The positive clones (CEPH human mega YAC clones: 761-G10, 797-G4, 842-G1, 842-G3, 910-G12, 945-C12; ICI human YAC clones: 13I-E10, 13I-G11, 14I-G12, 16F-H2, 1E-F6, 21E-G5, 30A-D10, 30H-D2, 33D-C4, 35B-D2, 18B-E3, 31H-A4, 40D-E8, 8D-E12, 9H-F10) were obtained from the UK HGMP Resource Centre . Clones were grown up in casamino acid selective broth overnight and harvested by centrifugation. The pellet was then washed twice in 0.5 ml 100 mM Tris-HCl, pH7.5, 0.5 M EDTA buffer. After a second round of centrifugation the pellet was resuspended in molten 1% LMP agarose in 5 mM Tris-HCl, pH7.5, 0.05 M EDTA, 10 mM NaCl with 100 mug of Zymolase. The agarose was cooled and the resultant plugs were incubated overnight at 37degreesC in 50 ml of 0.5 M EDTA, 10 mM Tris-HCl, pH7.5, 10 mM NaCl. The buffer was replaced with fresh solution to which 100 mul of 40% Sarkosyl NL30 and 50 mul Proteinase K (1 mg/ml) was added and the plugs were incubated overnight at 50degreesC.
###end p 24
###begin p 25
###xml 899 904 <span type="species:ncbi:4932">yeast</span>
The YAC chromosomal DNA was purified and separated for sizing by CHEF electrophoresis. The switching angle was 120degrees, using a CHEFtrade mark electrophoresis tank (Bio Rad), run for 16 hours at 6 V/cm, 10degreesC with an initial pulse time of 30 sec to a final pulse time of 90 sec. DNA was stained with (20 mg/ml) ethidium bromide solution (BDH) for 2 hours and visualized under ultra-violet illumination. Southern blotting and membrane hybridisation of CHEF gels were performed on Hybond-Ntrade mark membranes (Amersham). DNA was immobilised by heating the membrane to 80degreesC in vacuum for 1 hour in a gel dryer (Bio-Rad). Radio-labelled YAC vector-specific probes were generated using the Megaprime random primer kit (Amersham) as described in the manufacturer's instructions, using PCR products as a template. Sizes were estimated based on comparisons with the known sizes of the native yeast chromosomes.
###end p 25
###begin title 26
Genetic mapping
###end title 26
###begin p 27
The microsatellite markers: Cen-D2157, D2S124, D2S2330, CHLC.GATA71B02 (D2S1776), D2S2345, CHLC.GATA71D01, D2S294, AFMA109YC1, D2S376, D2S2284, D2S2177, D2S2194, D2S333, D2S2302, D2S2381, D2S326, AFMA304WB1, D2S138, D2S148, D2S300-Tel, were amplified using fluorescently labelled primers (Lifetech) previously designed by the Whitehead Institute or on the GDB database , , . These primers were used to amplify microsatellite marker alleles from individuals by PCR. Individual alleles were identified by denaturing polyacrylamide gel electrophoresis on an ABI Prism 377 sequencer and analysed using Genescantrade mark and Genotypertrade mark (version 1.1.1) software (Applied Biosystems).
###end p 27
###begin title 28
Single-strand conformational polymorphism analysis
###end title 28
###begin p 29
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAD1 </italic>
###xml 79 80 79 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
GAD1 exon sequences were amplified by PCR using the primers described in Table 1. SSCP was performed on GeneGel Excel (Amersham), using a 12.5/24 gel (14degreesC, 600 V, 25 mA, 15 W for 80 min) and the DNA was visualised by silver staining as per the manufacturer's instructions.
###end p 29
###begin p 30
Oligonucleotide primer used in the amplification of GAD1 exons.
###end p 30
###begin title 31
Sequencing of GAD1 exon sequences
###end title 31
###begin p 32
###xml 37 42 37 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAD1 </italic>
###xml 127 128 127 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
Primers used to amplify the exons of GAD1 were designed from the sequence of BAC RP11-570c16 and obtained from Lifetech (Table 1). PCR products were purified from agarose gels using QIAquick gel extraction kits (Quiagen), sequenced using ABI PRISM Big Dye Terminator Cycle Sequencing Ready Reaction Kits (Applied Biosystems) and then analysed using an ABI Prism 377 automated sequencer.
###end p 32
###begin title 33
Results
###end title 33
###begin title 34
Physical map of the spastic CP locus
###end title 34
###begin p 35
###xml 154 155 154 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 518 519 518 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
An integrated YAC (ICI and CEPH mega YAC libraries) and RP-9 PAC (HGMP Resource Centre) contig for the interval D2S2157 to D2S385 was constructed (Figure 1). This map provided physical continuity connecting 25 loci from centromere to telomere spanning the entire 2q24.3-31.1 cytogenetic band region. These data were combined with BAC contigs, constructed at Washington University , in an attempt to form an ordered BAC/YAC contig across the minimum region of interest. Selected YACs from this contig were sized (Table 2) enabling the physical length of the region to be estimated. The partial contig map included 3 identified CEPH mega-YAC contigs (contig 1: 945-C12; 912-B6; 744-G6; 797-G4; 761-G10; contig 2: 752-G9; 757-E1; 807-H5; 842-G1; 842-G3 and contig 3: 964-H5; 935-E10; 855-H2; 785-G8; 963-D11; 751-H3). The size of the region incorporating the three contigs was estimated to be at least 2870 kb. The sizes of the ICI YACs were estimated to encompass a minimum locus of 2940 kb. Microsatellite markers, ESTs and known genes, mapped to this region by NCBI, were then located on the physical contig by PCR and BLAST sequence homology searches of the Washington University BAC contigs. The expression profiles of unidentified EST clusters were determined and used to form EST "bins". These contained groups of ESTs, which mapped to adjacent locations and showed common expression profiles, suggesting that they might represent different exons of the same gene. This placement of known genes and ESTs onto the physical map provided an annotation of the gene content of the region, at the time was constructed before any such facility was available from the HGP, as the focus for candidate disease gene selection.
###end p 35
###begin p 36
###xml 0 84 0 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">An integrated physical YAC contig spanning the human chromosome 2 spastic CP locus. </italic>
###xml 0 84 0 84 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>An integrated physical YAC contig spanning the human chromosome 2 spastic CP locus. </italic></bold>
###xml 47 52 <span type="species:ncbi:9606">human</span>
An integrated physical YAC contig spanning the human chromosome 2 spastic CP locus. This was constructed against a framework of microsatellite and STS markers, to incorporate the region of linkage identified by genotyping data. The positions of microsatellite and STS markers are represented numerically left to right from centromere to telomere. These loci 1-25 were mapped arbitrarily equi-distant onto the contig, in the following order: Cen-(1) D2S2157; (2) D2S382; (3) WI-18792; (4) D2S124; (5) D2S111; (6) D2S2384; (7) D2S2330; (8) D2S399; (9) D2S2345; (10) D2S294; (11) D2S2188; (12) D2S2284; (13) D2S2177; (14) D2S335; (15) D2S326; (16) D2S2381; (17) D2S2302; (18) D2S2307; (19) D2S2257; (20) D2S2314; (21) D2S138; (22) D2S148; (23) D2S2173; (24) D2S300; (25) D2S385-Tel.
###end p 36
###begin p 37
###xml 251 256 <span type="species:ncbi:4932">yeast</span>
Approximate sizes of YAC clones spanning the 2q24-31.1 autosomal recessive spastic CP disease gene locus, used to estimate the minimum physical size of the region (kb). The CEPH MEGA and ICI YACs were sized using CHEF PFGE compared against the native yeast chromosomes. This confirmed the estimated size ranges of the YAC inserts, predicted by the Whitehead Institute (WI) database of YAC clones.
###end p 37
###begin title 38
Genetic mapping data
###end title 38
###begin p 39
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 291 292 291 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
From the PAC/YAC contig, 20 polymorphic microsatellite markers were identified that span the chromosome 2q24-31.1 CP critical region. These were then used, with informed consent and local research ethics committee approval, in the detailed mapping of previously linked families [10] (Figure 2). These data did not support the presence of a founder mutation for autosomal recessive spastic CP, in that families did not share a common haplotype across the minimal homozygous region between D2S2345 and D2S326.
###end p 39
###begin p 40
###xml 0 109 0 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Annotation of two pedigrees of spastic autosomal recessive CP families and corresponding linkage mapping data</italic>
###xml 0 109 0 109 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Annotation of two pedigrees of spastic autosomal recessive CP families and corresponding linkage mapping data</italic></bold>
Annotation of two pedigrees of spastic autosomal recessive CP families and corresponding linkage mapping data. The markers shown are those that demonstrate the minimal homozygous region between the affected individuals of both families.
###end p 40
###begin title 41
Sequence analysis of GAD1
###end title 41
###begin p 42
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAD1 </italic>
###xml 229 234 229 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAD1 </italic>
###xml 396 401 396 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A,3B</xref>
###xml 852 853 852 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 865 866 865 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 448 456 <span type="species:ncbi:9606">patients</span>
GAD1 was sequenced in affected and unaffected individuals in both families ascertained. In order to differentiate possible disease-causing mutations from polymorphisms, 100 control individuals were screened by SSCP to detect any GAD1 sequence variations in the normal population. SSCP variants were then sequenced to identify the underlying nucleotide substitutions. An homozygous G(36)C (Figure 3A,3B) nucleotide change was observed in 4 affected patients, which generated a Ser(12)Cys amino acid substitution. No obligate carriers were identified for this mutation. This variant has not been previously described and was not present in 200 normal chromosomes. A number of other sequence changes were detected, but none of these resulted in amino acid changes. These variants and all those recorded previously in the literature are presented in Table 4 and Figure 4. For those rare variants in the databases, which result in amino acid changes, no homozygous or compound heterozygous individuals have yet been described.
###end p 42
###begin p 43
###xml 0 108 0 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Electropherograms of the sequence of the exon 1 SNP of GAD1 identified in the process of mutational analysis</italic>
###xml 0 108 0 108 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Electropherograms of the sequence of the exon 1 SNP of GAD1 identified in the process of mutational analysis</italic></bold>
Electropherograms of the sequence of the exon 1 SNP of GAD1 identified in the process of mutational analysis. (A) and (B) show the normal C variant in the forward and reverse directions, respectively. (C) and (D) show the alternative G variant in the forward and reverse directions, respectively. This variant was only found in affected individuals of family B. No heterozygous individuals were identified for this nucleotide variant.
###end p 43
###begin p 44
###xml 444 479 444 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Denotes an unaffected family member</italic>
Autozygosity mapping data generated by genotyping eight members of the two autosomal recessive spastic CP families. Subjects 4718, 4719, 4720 and 4722 represent family A; subjects 4578, 4579, 4581 and 4679 represent family B as demonstrated in Figure 2. This Table is organised according to the definitive marker order determined from current databases and the physical contig mapping undertaken. The minimum homozygous region is highlighted. *Denotes an unaffected family member.
###end p 44
###begin p 45
###xml 0 115 0 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">An annotation of the distribution of single nucleotide substitutions identified in the open reading frame of GAD1. </italic>
###xml 0 115 0 115 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>An annotation of the distribution of single nucleotide substitutions identified in the open reading frame of GAD1. </italic></bold>
###xml 505 506 505 506 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 516 517 516 517 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 528 529 528 529 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 540 541 540 541 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 552 553 552 553 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E</bold>
###xml 564 565 564 565 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F</bold>
###xml 576 577 576 577 <bold xmlns:xlink="http://www.w3.org/1999/xlink">G</bold>
###xml 589 590 589 590 <bold xmlns:xlink="http://www.w3.org/1999/xlink">H</bold>
###xml 602 603 602 603 <bold xmlns:xlink="http://www.w3.org/1999/xlink">i</bold>
###xml 615 616 615 616 <bold xmlns:xlink="http://www.w3.org/1999/xlink">J</bold>
###xml 628 629 628 629 <bold xmlns:xlink="http://www.w3.org/1999/xlink">k</bold>
###xml 641 642 641 642 <bold xmlns:xlink="http://www.w3.org/1999/xlink">l</bold>
###xml 654 655 654 655 <bold xmlns:xlink="http://www.w3.org/1999/xlink">m</bold>
An annotation of the distribution of single nucleotide substitutions identified in the open reading frame of GAD1. The approximate positions with respect to intron-exon of the open reading frame structure are illustrated. These were determined by sequencing of the probands in this study, from published data and from the NCBI collated database of SNPs. The letters refer to the SNPs listed in Table 4. Upper case letters refer to SNPs in the cDNA and lower case letters indicate SNPs in the genomic DNA. A: G(36)C, B: G(210)A, C: G(253)C, D: T(315)C, E: A(407)G, F: C(696)T, G: C(1506)T, H: C(1575)T, i: T(1625)G, J: C(1654)T, k: A(1659)G, l: G(1799)A, m: C(1899)A.
###end p 45
###begin title 46
Discussion
###end title 46
###begin p 47
###xml 84 85 84 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 375 377 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 483 484 483 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 485 487 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 568 570 568 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 580 585 580 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 588 590 588 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
CP is a term used as a collective definition for a group of neurological disorders [3]. The pathophysiology in most cases is poorly understood, but includes genetic syndromes, congenital malformation, infective intra-uterine encephalitis, cerebral haemorrhage or infarction, ischemic damage, periventricular leukomalacia (PVL), and non-infarctive telencephalic leukomalacia [11]. The contribution of Mendelian inherited cases of CP accounts for approximately 2% of the total number [2,22]. A non-progressive form of autosomal recessive spastic CP has been identified [13]. McHale et al. [10] succeeded in identifying a 5 cM region on chromosome 2q24-31.1, which segregated with disease in consanguineous families. Linkage analysis identified a locus between markers D2S124 and D2S333, which produced a LOD score of 5.75, sufficient to warrant the further investigation described herein.
###end p 47
###begin p 48
###xml 272 273 272 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 552 554 552 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1066 1067 1066 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
To refine and confirm the genetic marker order across a region, which was incompletely sequenced at the time, we used YAC and PAC clones to construct a physical framework and performed PCR to map ESTs and microsatellite markers to clones within the partial contig (Figure 1). When this contig was integrated with the BAC sequence contigs, rearrangement of the BAC order was necessary. With each subsequent DNA sequence update, the degree of inconsistency was reduced and this led to revision of microsatellite order compared with that used previously [10]. Using the YAC sizes, the sizes of gaps in the BAC contig could be estimated. Having generated a detailed map spanning the region, we selected microsatellite markers at evenly spaced intervals across the locus. These markers were used to refine the minimum region homozygous by descent in linked families, to between the markers D2S2345 and D2S326. The physical size of the region between these markers is approximately 0.5 cM. There was no suggestion of a founder haplotype common to the two families (Figure 2).
###end p 48
###begin p 49
###xml 15 20 <span type="species:ncbi:9606">Human</span>
The Goldenpath Human Genome Working Draft Assembly 2001, is an annotation of the Washington BAC contig, combining sequence data of BACs, ESTs, known genes and hypothetical genes. We mapped ESTs and known, uncharacterised or hypothetical genes on the basis of sequence homology (NCBI , Whitehead  and Goldenpath databases), onto our YAC/PAC contig. ESTs were then collated according to their expression profiles to produce a "binned" EST map, on which candidate gene selection could be based. This reduced the number of hypothetical genes in the region and allowed the combination of genetic, physical mapping and expression data, into a single comprehensive map.
###end p 49
###begin p 50
###xml 56 60 56 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAD1</italic>
###xml 79 81 79 81 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67</sub>
###xml 170 173 170 173 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67 </sub>
###xml 321 323 321 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 435 437 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 533 535 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
One interesting candidate within the minimal region was GAD1, which encodes GAD67. Expression of its transcript is ubiquitous, including the CNS. The main function of GAD67 is to catalyze the conversion of the excitatory amino acid and neurotransmitter glutamate to GABA, the main inhibitory neurotransmitter in the CNS [23]. In the developing CNS, GABA has an important role in neuronal differentiation and the control of plasticity [21]. GABA has also been implicated in the pathogenesis of various seizure and movement disorders [20].
###end p 50
###begin p 51
###xml 96 101 96 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAD1 </italic>
###xml 105 110 105 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAD2 </italic>
###xml 271 273 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 421 423 421 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 424 426 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 427 429 427 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
Vertebrates have two separate genes coding for GAD, which produce distinct forms of the enzyme. GAD1 and GAD2 have diverged relatively recently in evolution, as indicated by their degree of sequence homology and the retention of common intron-exon boundary splice sites [17] (Figure 5A). The variants of GAD differ in molecular weight, cellular and sub-cellular localisation, and their interaction with the cofactor PLP [18,20,24].
###end p 51
###begin p 52
###xml 0 113 0 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Three illustrations of the genomic, protein and comparative sequence homologies of the different species of GAD. </italic>
###xml 0 113 0 113 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Three illustrations of the genomic, protein and comparative sequence homologies of the different species of GAD. </italic></bold>
###xml 143 147 143 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAD1</italic>
###xml 151 153 151 153 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25</sub>
###xml 148 153 148 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAD<sub>25</sub></italic>
###xml 154 159 154 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAD2 </italic>
###xml 163 178 163 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila Gad1</italic>
###xml 228 230 228 230 <sub xmlns:xlink="http://www.w3.org/1999/xlink">65</sub>
###xml 234 236 234 236 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25</sub>
###xml 240 243 240 243 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67 </sub>
###xml 247 258 247 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 398 400 398 400 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67</sub>
###xml 404 407 404 407 <sub xmlns:xlink="http://www.w3.org/1999/xlink">65 </sub>
###xml 411 422 411 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 163 173 <span type="species:ncbi:7227">Drosophila</span>
###xml 247 257 <span type="species:ncbi:7227">Drosophila</span>
###xml 411 421 <span type="species:ncbi:7227">Drosophila</span>
Three illustrations of the genomic, protein and comparative sequence homologies of the different species of GAD. (A) The genomic structures of GAD1/GAD25/GAD2 and Drosophila Gad1. (B) Comparative protein domain structures of GAD65/GAD25/GAD67 and Drosophila Gad1. (Numbers represent approximate amino acid residues). (C) Schematic illustrating the relative homology of the protein structures of GAD67/GAD65 and Drosophila Gad1.
###end p 52
###begin p 53
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAD2</italic>
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 235 239 235 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAD1</italic>
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 304 306 304 306 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25</sub>
###xml 347 352 347 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAD1 </italic>
###xml 414 419 414 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAD1 </italic>
###xml 554 556 554 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 562 565 562 565 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67 </sub>
###xml 572 575 572 575 <sub xmlns:xlink="http://www.w3.org/1999/xlink">65 </sub>
###xml 621 623 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
###xml 630 631 630 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 664 667 664 667 <sub xmlns:xlink="http://www.w3.org/1999/xlink">65 </sub>
###xml 683 685 683 685 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67</sub>
###xml 720 721 720 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 820 822 820 822 <sub xmlns:xlink="http://www.w3.org/1999/xlink">65</sub>
###xml 826 829 826 829 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67 </sub>
###xml 843 845 843 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 852 853 852 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 897 900 897 900 <sub xmlns:xlink="http://www.w3.org/1999/xlink">65 </sub>
###xml 918 920 918 920 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67</sub>
###xml 1000 1002 1000 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1012 1013 1012 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 457 462 <span type="species:ncbi:9606">human</span>
###xml 541 546 <span type="species:ncbi:10090">mouse</span>
GAD2, located at 10p13-p11.2, is transcribed to produce a 5.6 kb mRNA in islets and brain, encoding a 65 kDa protein (585 AA residues). The 67 kDa (594 AA residues) form [17] is localised to 2q25-26 and encoded by a 3.7 kb transcript (GAD1) [23]. There is also evidence for a 25 kDa inactive protein (GAD25) produced from an alternatively spliced GAD1 transcript of 2 kb that contains an in-frame stop codon. This GAD1 splice variant has only been found in human islets, testis and adrenal cortex, although the homologue is present in fetal mouse brain [25]. GAD67 and GAD65 consist of two major sequence domains (Figure 5B). The N-termini (AA residues 1-94 in GAD65 and 1-101 in GAD67) demonstrate ~23% homology. These N-terminal domains are thought to be responsible for sub-cellular targeting and the formation of GAD65-GAD67 heterodimers [26]. The C-terminal domains (AA residues 96-585 in GAD65 and 102-594 in GAD67) contain the catalytic site, with ~73% sequence identity between the isoforms [19] (Figure 5).
###end p 53
###begin p 54
###xml 15 18 15 18 <sub xmlns:xlink="http://www.w3.org/1999/xlink">65 </sub>
###xml 126 129 126 129 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67 </sub>
###xml 218 220 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 384 387 384 387 <sub xmlns:xlink="http://www.w3.org/1999/xlink">65 </sub>
###xml 540 542 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 567 570 567 570 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67 </sub>
###xml 679 681 679 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 689 694 689 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 697 699 697 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 716 719 716 719 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25 </sub>
In the CNS, GAD65 appears to be preferentially distributed in axon terminals and the associated synaptic vesicles, whereas GAD67 is also located in the cell bodies and more uniformly distributed throughout the neuron [24]. This suggests that each GAD isoform is involved in the synthesis of GABA in different sub-cellular compartments [21]. This is supported by the discovery that GAD65 is the main source of apoGAD (an inactive reservoir), which responds to short-term changes in neuronal activity and is more responsive to levels of PLP [18]. On the other hand, GAD67 predominantly exists bound to the PLP cofactor (holoGAD), providing a constitutive level of GABA production [20]. Bond et al. [27] showed that GAD25 is expressed in a temporally controlled manner, in the developing striatum and cortex in rodents, suggesting this may provide a mechanism of regulating GABA production in differentiating neurons.
###end p 54
###begin p 55
###xml 6 11 6 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 14 16 14 16 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 120 124 120 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gad2</italic>
###xml 342 345 342 345 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67 </sub>
###xml 419 421 419 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 424 432 424 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gad1-/- </italic>
###xml 559 561 559 561 <sup xmlns:xlink="http://www.w3.org/1999/xlink">14</sup>
###xml 585 587 585 587 <sup xmlns:xlink="http://www.w3.org/1999/xlink">14</sup>
###xml 589 591 589 591 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 741 743 741 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 895 898 895 898 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67 </sub>
###xml 921 923 921 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1149 1151 1146 1148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1152 1154 1149 1151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 128 132 <span type="species:ncbi:10090">mice</span>
###xml 432 436 <span type="species:ncbi:10090">mice</span>
###xml 767 771 <span type="species:ncbi:10090">mice</span>
###xml 949 953 <span type="species:ncbi:10090">mice</span>
Asada et al. [28] undertook the selective elimination of each GAD isoform in order to determine their respective roles. Gad2-/- mice are slightly more susceptible to seizures, consistent with an excitatory increase in the relative ratio of glutamate/GABA. However, they showed no obvious overall change in neuronal GABA content. Therefore GAD67 alone appears to produce sufficient GABA for effective neurotransmission [21]. Gad1-/- mice demonstrated a decrease of ~20% in total glutamate decarboxylase activity at birth. This was assayed by the conversion of 14C-labelled glutamate to 14CO2 in the presence of PLP. There was also a marked (7%) reduction in total GABA content in cerebral cortex homogenate measured by liquid chromatography [28]. Unfortunately, these mice died neonatally of severe cleft palate, masking any potential neurological dysfunction and also illustrating a role for Gad67 in non-neural tissues [21]. It is of interest that mice with mutations in the beta-3 GABA receptor (GABRB3) at the Angelman syndrome (OMIM:105830) locus, also display cleft palate, implying a key role for GABA signalling in normal palate development [29,30].
###end p 55
###begin p 56
###xml 408 410 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 413 418 413 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAD1 </italic>
###xml 567 572 567 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAD1 </italic>
###xml 576 581 576 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAD2 </italic>
###xml 591 593 591 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
Pyridoxine-dependent epilepsy (PDE) is a rare autosomal recessive disorder (OMIM:266100), characterized by generalized seizures during the first hours of life. The associated pathology may result from an alteration in the binding of the co-factor PLP to GAD. Interestingly epilepsy is commonly associated with CP and grand mal epilepsy developed at age six months in the two linked pedigrees described here [10]. GAD1 mutation was previously suspected of being the cause of PDE. Linkage of pyridoxine-dependent epilepsy has however been reported to 5q31.2-31.3, with GAD1 and GAD2 excluded [31]. Decreased levels of brain and CSF GABA, increased levels of CSF and cortical glutamate, and decreased levels of PLP in the frontal cortex, have been described in this condition.
###end p 56
###begin p 57
###xml 3 6 3 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink">65 </sub>
###xml 13 16 13 16 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67 </sub>
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 252 255 252 255 <sub xmlns:xlink="http://www.w3.org/1999/xlink">65 </sub>
###xml 262 265 262 265 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67 </sub>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 636 638 636 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 746 748 746 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 64 70 <span type="species:ncbi:9606">Person</span>
###xml 427 435 <span type="species:ncbi:9606">patients</span>
GAD65 and GAD67 have been identified as auto-antigens in "Stiff Person Syndrome" (SPS, OMIM:184850), and in cerebellar ataxia [32-34]. GABA-mediated synaptic transmission is thought to be functionally impaired by the production of autoantibodies to GAD65 and GAD67 [35-37]. This results in a reduction in brain levels of GABA, prominent in the motor cortex, which can be demonstrated by Magnetic Resonance Imaging (MRI) in SPS patients. SPS is a disabling disorder characterised by muscle rigidity and episodic spasms of the musculature, thought to be due to autoimmune-mediated dysfunction of supraspinal GABAergic inhibitory neurons [38]. Hyperexcitability of the motor cortex in SPS has been demonstrated by transcranial magnetic stimulation [39].
###end p 57
###begin p 58
###xml 8 11 8 11 <sub xmlns:xlink="http://www.w3.org/1999/xlink">65 </sub>
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 197 199 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 361 363 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 680 682 680 682 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A </sub>
###xml 693 695 693 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 56 64 <span type="species:ncbi:9606">patients</span>
###xml 247 255 <span type="species:ncbi:9606">patients</span>
Anti-GAD65 auto-antibodies in the CSF of ataxic and SPS patients selectively suppress GABA-mediated transmission in cerebellar Purkinje cells, without affecting glutamate-mediated transmission [37,40]. Low CSF levels of GABA have been reported in patients with Kok disease (OMIM:149400 also known as hyperexplexia/exaggerated startle reaction/startle disease) [41]. The exact mechanism by which autoantibodies target these intracellular GAD antigens is not clear. However, it is interesting that SPS may also arise in individuals with autoantibodies to gephyrin, a cytosolic protein concentrated at the postsynaptic membrane of inhibitory synapses where it is associated with GABAA receptors [42]. This provides a further example of chronic rigidity and spasm possibly secondary to disruption of the inhibitory synapses.
###end p 58
###begin p 59
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CLN3 </italic>
###xml 125 129 125 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cln3</italic>
###xml 165 168 165 168 <sub xmlns:xlink="http://www.w3.org/1999/xlink">65 </sub>
###xml 264 266 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 429 433 429 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cln3</italic>
###xml 471 474 471 474 <sub xmlns:xlink="http://www.w3.org/1999/xlink">65 </sub>
###xml 139 143 <span type="species:ncbi:10090">mice</span>
###xml 275 279 <span type="species:ncbi:10090">mice</span>
###xml 443 447 <span type="species:ncbi:10090">mice</span>
###xml 507 515 <span type="species:ncbi:9606">patients</span>
Mutations in the CLN3 gene are thought to be responsible for the neurodegenerative disorder Batten disease (OMIM:204200). In cln3-knockout mice autoantibodies to GAD65 have been reported to be associated with brain tissue and result in inhibition of GAD activity [43]. These mice also demonstrate elevated brain glutamate levels as compared with controls, which may have a causative role in the astrocytic hypertrophy evident in cln3-knockout mice and along with anti-GAD65 autoantibodies in Batten disease patients may contribute to the associated preferential loss of GABAergic neurons.
###end p 59
###begin p 60
###xml 366 368 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 372 374 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 645 647 637 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
Drugs, which potentiate the action of GABA, such as benzodiazepines and baclofen, ameliorate muscle rigidity and spasticity. These GABA agonists are thought to counter disinhibition of the velocity-dependent increase in skeletal muscle during stretch reflexes, observed in spasticity, which is the result of inadequate presynaptic inhibition of the muscle spindles [44,35,37]. gamma-Vinyl-gamma-aminobutyric acid (GVG) is used to treat neurological disorders including epilepsy, tardive dyskinesia and spasticity. It has been reported that it is the GABA-elevating effect of this compound that is responsible for its anti-convulsive properties [20].
###end p 60
###begin p 61
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAD1 </italic>
###xml 226 227 226 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 375 378 375 378 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67 </sub>
###xml 441 443 441 443 <sub xmlns:xlink="http://www.w3.org/1999/xlink">65</sub>
###xml 474 475 474 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 498 499 498 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 515 518 515 518 <sub xmlns:xlink="http://www.w3.org/1999/xlink">65 </sub>
###xml 637 639 637 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 690 692 690 692 <sub xmlns:xlink="http://www.w3.org/1999/xlink">65</sub>
###xml 735 737 735 737 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67</sub>
###xml 872 874 872 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 880 883 880 883 <sub xmlns:xlink="http://www.w3.org/1999/xlink">65 </sub>
###xml 955 956 955 956 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1091 1092 1091 1092 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1117 1119 1117 1119 <sub xmlns:xlink="http://www.w3.org/1999/xlink">65</sub>
###xml 1196 1198 1196 1198 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67</sub>
###xml 1241 1243 1241 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 299 304 <span type="species:ncbi:9606">human</span>
###xml 305 310 <span type="species:ncbi:10090">mouse</span>
###xml 311 317 <span type="species:ncbi:9986">rabbit</span>
###xml 318 321 <span type="species:ncbi:9823">pig</span>
We have identified a GAD1 sequence change G(36)C, which segregates with autosomal recessive spastic CP in 4 affected siblings. This nucleotide substitution causes a missense mutation, changing serine (12) to a cysteine in the N-terminal domain. This serine residue is conserved between all mammals (human/mouse/rabbit/pig) for which data are available. The association of GAD67 with membranes requires formation of heteromeric links with GAD65, which are mediated via their N-terminal domains. The N-terminus of GAD65 is palmitoylated and binds to the cellular membrane. The first 27 amino acids appear to be essential in this function [32]. The palmitoylation of cysteines 30 and 45 of GAD65, and the inability of residues 1-29 of GAD67, to substitute for this region, highlights the potential impact on cellular localisation of a nucleotide substitution in this domain [20]. GAD65 also undergoes phosphorylation of the first four serine residues in the N-terminal domain. These post-translational modifications highlight the importance of the flexibility and accessibility of this domain. N-terminal epitopes of GAD65, in the region corresponding to the residue, which undergoes mutation in GAD67, are particularly prominent autoantigens [45].
###end p 61
###begin p 62
###xml 230 235 230 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gad1 </italic>
###xml 267 272 267 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gad1 </italic>
###xml 410 412 410 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 413 415 413 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 619 622 619 622 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25 </sub>
###xml 643 645 643 645 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67</sub>
###xml 792 794 792 794 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67</sub>
###xml 829 830 829 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 939 941 939 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 963 966 963 966 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25 </sub>
###xml 1007 1010 1007 1010 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67 </sub>
###xml 1081 1082 1081 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1122 1125 1122 1125 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25 </sub>
###xml 1132 1134 1132 1134 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67</sub>
###xml 1190 1192 1190 1192 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67</sub>
###xml 224 229 <span type="species:ncbi:10090">mouse</span>
###xml 566 569 <span type="species:ncbi:9606">man</span>
###xml 574 579 <span type="species:ncbi:10090">mouse</span>
###xml 711 719 <span type="species:ncbi:9606">patients</span>
S(12)C amino acid substitution may thus produce subtle effects on cellular localisation, protein-protein interactions and/or protein processing, with a subsequent effect on GABA production. This is not inconsistent with the mouse Gad1 knockout where complete loss of Gad1 enzymatic function (~20% reduction of total Gad activity in the cerebral cortex) resulted in a cleft palate phenotype and neonatal death [28,30]. There is redundancy of GABA production as a result of the presence of two GAD proteins, and the precise function of each isoform may differ between man and mouse. It is interesting to note that the GAD25 splice variant of GAD67, also contains the S(12)C amino acid substitution in affected CP patients. This truncated variant is identical to the first 213 amino acids of GAD67, with the addition of an extra 11 C-terminal residues. It lacks the binding site for the cofactor PLP and is believed to lack any GAD activity [25]. The function of GAD25 is not known, but it may compete with GAD67 for incorporation into protein complexes. Therefore the presence of an N-terminal mutation would affect both GAD25 and GAD67, and may disrupt a complex regulatory mechanism for GAD67.
###end p 62
###begin title 63
Conclusions
###end title 63
###begin p 64
###xml 630 633 630 633 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67 </sub>
###xml 647 650 647 650 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25 </sub>
This study illustrates the difficulty of gene cloning in rare autosomal recessive diseases mapped in small, consanguineous pedigrees. Identification of an ancestral haplotype allows refinement of the locus, but this has not been possible in this example. Within the minimal linkage region, any sequence change will segregate with the disease phenotype. Detection of a nonsense mutation leading to a protein truncation would provide compelling support for a mutation as causative. However, in the present example we have not seen such a mutation in the candidate gene so far examined. We are now expressing the variant forms of GAD67 (S12C) and GAD25 (S12C), as recombinant proteins, to assess catalytic activity and binding properties with respect to their normal counterparts. However, it may well prove difficult to detect subtle effects based on sub-cellular localisation changes in the mutant proteins, or changes in post-translational modification patterns.
###end p 64
###begin p 65
###xml 187 192 187 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAD1 </italic>
###xml 209 217 209 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gad1-/- </italic>
###xml 393 396 393 396 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67 </sub>
###xml 612 614 612 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 615 617 615 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 217 222 <span type="species:ncbi:10090">mouse</span>
###xml 425 433 <span type="species:ncbi:9606">patients</span>
Stability of the mRNA transcripts from these variants will be assessed by transfection studies in neuronal cells. Eventually, it would be of interest to attempt knock-in experiments with GAD1 (G36C), into the Gad1-/- mouse to see if this can rescue the cleft palate phenotype and reveal a CP-like picture. These experiments will be reported elsewhere. However, the possibility that reduced GAD67 activity may cause CP in the patients studied herein, in a manner reminiscent of that seen in SPS, leads us to report our findings at this stage. The success reported in treating SPS with intravenous immunoglobulin [40,46], suggests further evaluation of GABA agonists in the management of this difficult clinical problem.
###end p 65
###begin title 66
Abbreviations
###end title 66
###begin p 67
BAC Bacterial artificial chromosome
###end p 67
###begin p 68
BLAST Basic local alignment search tool
###end p 68
###begin p 69
CEPH Centre d'Etude du Polymorphisme Humain
###end p 69
###begin p 70
CHEF Contour-clamped homogenous electric field
###end p 70
###begin p 71
CNS Central nervous system
###end p 71
###begin p 72
CP Cerebral Palsy
###end p 72
###begin p 73
CSF Cerebrospinal fluid
###end p 73
###begin p 74
DNA Deoxyribonucleic acid
###end p 74
###begin p 75
EST Expressed sequence tag
###end p 75
###begin p 76
GABA Gamma-aminobutyric acid
###end p 76
###begin p 77
GAD L-Glutamate decarboxylase
###end p 77
###begin p 78
GVG Gamma-vinyl-gamma aminobutyric acid
###end p 78
###begin p 79
###xml 5 10 <span type="species:ncbi:9606">Human</span>
HGMP Human genome mapping project
###end p 79
###begin p 80
IDDM Type 1 Insulin-Dependent Diabetes Mellitus
###end p 80
###begin p 81
MRI Magnetic resonance imaging
###end p 81
###begin p 82
NCBI National Centre for Biotechnology Information
###end p 82
###begin p 83
PAC Plasmid artificial chromosome
###end p 83
###begin p 84
PCR Polymerase chain reaction
###end p 84
###begin p 85
PDE Pyridoxine-dependent epilepsy
###end p 85
###begin p 86
PFGE Pulse field gel electrophoresis
###end p 86
###begin p 87
PLP Pyridoxal 5'-phosphate
###end p 87
###begin p 88
PVL Periventricular leukomalacia
###end p 88
###begin p 89
SPG Spastic paraplegia
###end p 89
###begin p 90
###xml 10 16 <span type="species:ncbi:9606">Person</span>
SPS Stiff Person Syndrome
###end p 90
###begin p 91
SSCP Single-strand conformational polymorphism
###end p 91
###begin p 92
STS Sequence tagged site
###end p 92
###begin p 93
###xml 4 9 <span type="species:ncbi:4932">Yeast</span>
YAC Yeast artificial chromosome
###end p 93
###begin title 94
Competing interests
###end title 94
###begin p 95
The author(s) declare that they have no competing interests.
###end p 95
###begin title 96
Authors' contributions
###end title 96
###begin p 97
CNL carried out the molecular genetic studies, sequencing and drafted the manuscript. The YAC mapping work was undertaken by JPL and CNL. AFM, DTB and IMC conceived the study and participated in the design and coordination, they also secured financial sponsorship from the Wellcome Trust and MRC. RA, SM, ERM and CGW recruited and gained consent from the families detailed in this study. All authors read and approved the final manuscript.
###end p 97
###begin title 98
Pre-publication history
###end title 98
###begin p 99
The pre-publication history for this paper can be accessed here:
###end p 99
###begin p 100

###end p 100
###begin title 101
Acknowledgements
###end title 101
###begin p 102
Research in the authors' laboratory is supported by the Wellcome Trust, MRC, CRUK and Yorkshire Cancer Research. CNL has an MRC PhD studentship. This paper is dedicated to the late Prof. S. Bundey, University of Birmingham.
###end p 102
###begin article-title 103
Cerebral palsy
###end article-title 103
###begin article-title 104
Identical syndromes of cerebral palsy in the same family
###end article-title 104
###begin article-title 105
Cerebral palsy
###end article-title 105
###begin article-title 106
Case control study of intrapartum care, cerebral palsy and perinatal death
###end article-title 106
###begin article-title 107
Birthweight specific trends in cerebral palsy
###end article-title 107
###begin article-title 108
The causes of cerebral palsy. Recent evidence
###end article-title 108
###begin article-title 109
The Origins of Cerebral Palsy
###end article-title 109
###begin article-title 110
A gene for autosomal recessive symmetrical spastic cerebral palsy maps to chromosome 2q24-25
###end article-title 110
###begin article-title 111
###xml 32 40 <span type="species:ncbi:9606">children</span>
Recurrence risks in families of children with symmetrical spasticity
###end article-title 111
###begin article-title 112
###xml 44 52 <span type="species:ncbi:9606">patients</span>
Symmetry of neurological signs in Pakistani patients with probable inherited spastic cerebral palsy
###end article-title 112
###begin article-title 113
A gene for ataxic cerebral palsy maps to chromosome 9p12-q12
###end article-title 113
###begin article-title 114
Glutamic acid decarboxylase - gene to antigen to disease
###end article-title 114
###begin article-title 115
Multiplicity of glutamic acid decarboxylases (GAD) in vertebrates: molecular phylogeny and evidence for a new GAD paralog
###end article-title 115
###begin article-title 116
Two genes encode distinct glutamate decarboxylases
###end article-title 116
###begin article-title 117
Structural features and regulatory properties of the brain glutamate decarboxylases
###end article-title 117
###begin article-title 118
Regulation of gama-aminobutyric acid synthesis in the brain
###end article-title 118
###begin article-title 119
###xml 51 54 51 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67 </sub>
###xml 73 76 73 76 <sub xmlns:xlink="http://www.w3.org/1999/xlink">65 </sub>
###xml 95 98 <span type="species:ncbi:10116">rat</span>
Localization of cells preferentially expressing GAD67 with negligible GAD65 transcripts in the rat hippocampus. A double in situ hybridization study
###end article-title 119
###begin article-title 120
Genetic aspects of cerebral palsy
###end article-title 120
###begin article-title 121
###xml 4 9 <span type="species:ncbi:9606">human</span>
Two human glutamate decarboxylases, 65-kDa GAD and 67-kDa GAD, are each encoded by a single gene
###end article-title 121
###begin article-title 122
###xml 100 103 100 103 <sub xmlns:xlink="http://www.w3.org/1999/xlink">65 </sub>
###xml 110 112 110 112 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67</sub>
###xml 143 146 <span type="species:ncbi:10116">rat</span>
Differential regulation of mRNA levels encoding for the two isoforms of glutamate decarboxylase (GAD65 and GAD67) by dopamine receptors in the rat striatum
###end article-title 122
###begin article-title 123
###xml 27 30 27 30 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67 </sub>
###xml 105 110 <span type="species:ncbi:9606">human</span>
Alternative splicing of GAD67 results in the synthesis of a third form of glutamic-acid decarboxylase in human islets and other non-neural tissues
###end article-title 123
###begin article-title 124
###xml 43 48 43 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAD1 </italic>
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAD2</italic>
###xml 106 109 106 109 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67 </sub>
###xml 116 118 116 118 <sub xmlns:xlink="http://www.w3.org/1999/xlink">65</sub>
###xml 71 76 <span type="species:ncbi:9606">human</span>
The exon-intron organization of the genes (GAD1 and GAD2) encoding two human glutamate decarboxylases (GAD67 and GAD65) suggests that they derive from a common ancestral GAD
###end article-title 124
###begin article-title 125
Developmentally regulated expression of an exon containing a stop codon in the gene for glutamic acid decarboxlase
###end article-title 125
###begin article-title 126
###xml 60 64 <span type="species:ncbi:10090">mice</span>
Cleft palate and decreased brain gamma-aminobutyric acid in mice lacking the 67-kDa isoform of glutamic acid decarboxylase
###end article-title 126
###begin article-title 127
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice devoid of gamma-aminobutyrate type A receptor beta3 subunit have epilepsy, cleft palate, and hypersensitive behaviour
###end article-title 127
###begin article-title 128
###xml 16 20 <span type="species:ncbi:10090">mice</span>
Cleft palate in mice with a targeted mutation in the gamma-aminobutyric acid-producing enzyme glutamic acid decarboxylase 67
###end article-title 128
###begin article-title 129
A gene for pyridoxine-dependent epilepsy maps to chromosome 5q31
###end article-title 129
###begin article-title 130
###xml 25 28 <span type="species:ncbi:9606">Man</span>
GAD, diabetes, and Stiff-Man syndrome: some progress and more questions
###end article-title 130
###begin article-title 131
###xml 6 12 <span type="species:ncbi:9606">person</span>
Stiff-person syndrome associated with cerebellar ataxia and high glutamic acid decarboxylase antibody titre
###end article-title 131
###begin article-title 132
Antibodies against glutamic acid decarboxylase: prevalence in neurological diseases
###end article-title 132
###begin article-title 133
###xml 103 106 <span type="species:ncbi:9606">man</span>
Inhibition of gamma-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome
###end article-title 133
###begin article-title 134
Autosomal dominant cerebellar ataxia type I: oculomotor abnormalities in families with SCA1, SCA2, and SCA3
###end article-title 134
###begin article-title 135
Presynaptic impairment of cerebellar inhibitory synapses by an autoantibody to glutamate decarboxylase
###end article-title 135
###begin article-title 136
###xml 10 16 <span type="species:ncbi:9606">person</span>
The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid
###end article-title 136
###begin article-title 137
###xml 35 41 <span type="species:ncbi:9606">person</span>
Motor cortex excitability in stiff-person syndrome
###end article-title 137
###begin article-title 138
###xml 84 87 84 87 <sub xmlns:xlink="http://www.w3.org/1999/xlink">65 </sub>
###xml 6 12 <span type="species:ncbi:9606">person</span>
Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies
###end article-title 138
###begin article-title 139
Low cerebrospinal fluid concentration of free gamma-aminobutyric acid in startle disease
###end article-title 139
###begin article-title 140
###xml 34 37 <span type="species:ncbi:9606">Man</span>
Autoimmunity to gephyrin in Stiff-Man syndrome
###end article-title 140
###begin article-title 141
An autoantibody inhibitory to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease
###end article-title 141
###begin article-title 142
A signal located within amino acids 1-27 of GAD65 is required for its targeting to the Golgi complex region
###end article-title 142
###begin article-title 143
###xml 57 58 57 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 98 100 98 100 <sub xmlns:xlink="http://www.w3.org/1999/xlink">65</sub>
###xml 120 123 <span type="species:ncbi:9606">man</span>
Higher autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus
###end article-title 143
###begin article-title 144
Intravenous immunoglobulin in neurological disease: a specialist review
###end article-title 144
###begin article-title 145
Analysis of nine candidate genes for autism on chromosome 2q
###end article-title 145
###begin article-title 146
###xml 54 56 54 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink">67</sub>
Mutation screen of the glutamate decarboxylase 67 (GAD67) gene and haplotype association study to unipolar depression
###end article-title 146
###begin article-title 147
Mutation and polymorphic marker analyses of 65K- and 67K-glutamate decarboxylase genes in two families with pyridoxine-dependent epilepsy
###end article-title 147

